Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 9/20 | 0.54 |
| ▸ | F2 | P00734 | 7/20 | 0.54 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.49 |
| ▸ | RXRA | P19793 | 1/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.48 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2259105 | 0.88 | F10 (0.46) | F10F2KLKB1CARM1RXRA | |
| SCHEMBL2260910 | 0.87 | F10 (0.51) | F10F2KLKB1CARM1POLB | |
| SCHEMBL2261823 | 0.86 | F10 (0.51) | F10F2KLKB1PTGS2CARM1 | |
| SCHEMBL2260149 | 0.86 | F10 (0.50) | F10F2KLKB1PTGS2CARM1 | |
| SCHEMBL3473738 | 0.85 | PTGS2 (0.57) | PTGS2RXRANR1H2NR1H3POLB | |
| SCHEMBL2256471 | 0.85 | KLKB1 (0.51) | F10F2KLKB1CARM1 | |
| SCHEMBL14177269 | 0.83 | F10 (0.50) | F10F2KLKB1CARM1PRSS1 | |
| SCHEMBL2256640 | 0.82 | F10 (0.49) | F10F2KLKB1CARM1 | |
| SCHEMBL2257395 | 0.81 | PTGS2 (0.46) | KLKB1PTGS2RXRANR1H2NR1H3 | |
| SCHEMBL2259509 | 0.80 | CYP11B2 (0.51) | F10F2KLKB1CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100069367-A1 | LXR and FXR Modulators | EXELIXIS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069367-A1 | LXR and FXR Modulators | EXELIXIS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| WO-2008073825-A1 | LXR AND FXR MODULATORS | EXELIXIS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069367-A1 | LXR and FXR Modulators | NR1H3, NR1H2, NR1H4 | F10 143/4885F2 290/4885KLKB1 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.